The estimated Net Worth of Edward T Mathers is at least $394 Tisíc dollars as of 21 June 2024. Mr. Mathers owns over 3,000 units of Rhythm Pharmaceuticals stock worth over $147,930 and over the last 13 years he sold RYTM stock worth over $0. In addition, he makes $245,843 as Independent Director at Rhythm Pharmaceuticals.
Edward has made over 2 trades of the Rhythm Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of RYTM stock worth $147,930 on 21 June 2024.
The largest trade he's ever made was buying 333,333 units of Rhythm Pharmaceuticals stock on 17 July 2023 worth over $999,999. On average, Edward trades about 7,007 units every 7 days since 2011. As of 21 June 2024 he still owns at least 3,000 units of Rhythm Pharmaceuticals stock.
You can see the complete history of Mr. Mathers stock trades at the bottom of the page.
Edward T. Mathers serves as Independent Director of the Company. Mr. Mathers has served as a member of our Board since 2013. He has been a Partner at New Enterprise Associates, a venture capital firm, since 2008, and has also served as General Partner since October 2019. Mr. Mathers currently serves on the boards of directors of ObsEva SA, Trevi Therapeutics, Inc., Mirum Pharmaceuticals, Inc., and Synlogic, Inc.. Mr. Mathers also serves on the boards of directors of numerous private companies, including Akouos, Inc., Amplyx Pharmaceuticals, Inc., Envisia Therapeutics Inc., Inozyme Pharma, Inc., Shape Therapeutics, Inc., Reneo Pharmaceuticals, Inc., and Senti Biosciences Inc. Mr. Mathers previously served on the board of directors of Ra Pharmaceuticals, Inc. until its acquisition by UCB in April 2020 and Liquidia Technologies, Inc. until May 2019. Prior to joining New Enterprise Associates, Mr. Mathers served in various corporate development roles at MedImmune, Inc., a biotechnology company that was acquired by AstraZeneca PLC in 2007, culminating in the position of Executive Vice President, Corporate Development and Venture. In this role, he also led the company's venture capital subsidiary, MedImmune Ventures, Inc., from 2002 to 2008. Mr. Mathers was a director of MedImmune, LLC, from 2007 to 2008. From 2000 to 2002, Mr. Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, Inc., a biopharmaceutical company, which is now known as Nektar Therapeutics, Inc. Previously, for 15 years, Mr. Mathers was at Glaxo Wellcome, Inc., where he held sales and marketing positions of increasing responsibility. Mr. Mathers received a B.S. in chemistry from North Carolina State University.
As the Independent Director of Rhythm Pharmaceuticals, the total compensation of Edward Mathers at Rhythm Pharmaceuticals is $245,843. There are 13 executives at Rhythm Pharmaceuticals getting paid more, with Hunter Smith having the highest compensation of $1,922,850.
Edward Mathers is 60, he's been the Independent Director of Rhythm Pharmaceuticals since 2013. There are 5 older and 13 younger executives at Rhythm Pharmaceuticals. The oldest executive at Rhythm Pharmaceuticals Inc. is Dr. David P. Meeker M.D., 67, who is the Chairman, Pres & CEO.
Edward's mailing address filed with the SEC is 104 5TH AVE, , NEW YORK, NY, 10011.
Over the last 13 years, insiders at Rhythm Pharmaceuticals have traded over $83,445,563 worth of Rhythm Pharmaceuticals stock and bought 6,290,000 units worth $106,961,700 . The most active insiders traders include Forest Baskett, Scott D Sandell a Peter J Barris. On average, Rhythm Pharmaceuticals executives and independent directors trade stock every 17 days with the average trade being worth of $3,358,405. The most recent stock trade was executed by Pamela J. Cramer on 9 September 2024, trading 4,099 units of RYTM stock currently worth $77,963.
rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.
Rhythm Pharmaceuticals executives and other stock owners filed with the SEC include: